Published • loading... • Updated
CREATE Medicines Unveils All-RNA T-Cell Engineering Platform: RetroT Enables Site-Specific, Durable CAR integration In Vivo
- CREATE Medicines unveiled RetroT, an all-RNA gene integration system for T cells, emphasizing enhanced genomic safety and site-specific integration without double-strand DNA breaks, viral vectors, or DNA templates.
- CREATE Medicines successfully inserted a CD19-CAR transgene into human T cells using RetroT, confirmed by sequencing to show precise integration with no detectable off-target effects, as per their study findings.
- Robert Hofmeister, Chief Scientific Officer of CREATE Medicines, stated that RetroT enables durable gene insertion while allowing for scalable clinical applications with their targeted delivery platform.
- The RetroT platform utilizes human LINE-1 machinery to improve genomic safety and precision in gene editing over traditional methods, reducing off-target effects and genotoxicity.
Insights by Ground AI
54 Articles
54 Articles
CREATE Medicines Unveils All-RNA T-Cell Engineering Platform: RetroT Enables Site-Specific, Durable CAR integration In Vivo
All-RNA gene writing for T cells (RetroT): Utilizes human LINE-1 machinery to drive programmable, site-specific integration of multi-kb payloads, without DSBs, supporting a superior genomic safety profile.Successful genetic delivery of CART constructs to T cells
Coverage Details
Total News Sources54
Leaning Left4Leaning Right5Center18Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
15%
C 67%
R 18%
Factuality
To view factuality data please Upgrade to Premium
